Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Alterity Therapeutics Presents Data On Orthostatic Hypotension From Its ATH434-201 Phase 2 Clinical Study In Multiple System Atrophy

Author: Benzinga Newsdesk | November 10, 2025 07:27am

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that analyses on the baseline characteristics related to orthostatic hypotension (OH) from the ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System Atrophy (MSA) were featured in an oral presentation at the American Autonomic Society (AAS) 36th International Symposium on the Autonomic Nervous System that took place in Clearwater Beach, Florida, USA.

Posted In: ATHE


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist